Innovation Pharmaceuticals Inc (IPIX)

[sox040713]

BioHedge, it’s always good to see you posting again. Actually it’s not unrealistic for me to see 7 out of every 9 patients in the B arm don’t have severe OM and the % ends up with over 70%. Even if B-OM is 50% effective in the remaining patients in the B arm, you are looking at ~58% severe OM prevention.

Due to its very low systemic absorption of < 10 ng/mL, B-OM’s concentration can be tweaked from 3 mg/mL to further increase its efficacy without safety concerns. Either way, we have a very good home run hitter (Stanton?) in our lineup.